US · PALI
Palisade Bio, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Carlsbad, CA 92008
- Website
- palisadebio.com
Price · as of 2024-12-31
$1.99
Market cap 263.74M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $2.45 | +23.12% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $2,141,100.00 | $0.00 | $0.00 | ||
| 2011 | $1,345,500.00 | $541,425.99 | $0.00 | $0.00 | $8,221.40 |
| 2012 | $1,439,100.00 | $575,664.14 | $0.00 | $0.00 | $0.00 |
| 2013 | $4,141,800.00 | $1,657,000.52 | $0.00 | $0.00 | $14,670.84 |
| 2014 | $2,995,200.00 | $1,198,080.47 | $0.00 | $0.00 | $16,004.71 |
| 2015 | $1,158,300.00 | $463,478.61 | $0.00 | $0.00 | $6,815.13 |
| 2016 | $465,300.00 | $198,206.24 | $0.00 | $0.00 | $0.00 |
| 2017 | $153,000.00 | $61,645.27 | $55,431.55 | $0.00 | $0.00 |
| 2018 | $51,300.00 | $22,267.58 | $16,641.62 | $0.00 | $0.00 |
| 2019 | $3,600.00 | $1,883.42 | $0.00 | $0.00 | $5,579.82 |
| 2020 | $6,525.00 | $3,286.32 | |||
| 2021 | $780.00 | ||||
| 2022 | $30.30 | ||||
| 2023 | $5.85 | $1.52 | $0.00 | ||
| 2024 | $0.85 | $2.45 |
AI valuation
Our deep-learning model estimates Palisade Bio, Inc.'s (PALI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $2.45
- Current price
- $1.99
- AI upside
- +23.12%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PALI | Palisade Bio, Inc. | $1.99 | 263.74M | +23% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
| ASBP | Aspire Biopharma Holdings… | $1.39 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| ATHA | Athira Pharma, Inc. | $6.75 | 26.62M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| BCTX | BriaCell Therapeutics Cor… | $3.82 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CTXR | Citius Pharmaceuticals, I… | $0.74 | 8.27M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| DARE | Daré Bioscience, Inc. | $1.70 | 16.19M | +12,485% | -31% | — | +2,345% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| HOTH | Hoth Therapeutics, Inc. | $1.01 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| LPTX | Leap Therapeutics, Inc. | $0.62 | 25.83M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| PCSA | Processa Pharmaceuticals,… | $2.17 | 4.92M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
- CEO
- J. D. Finley
- Employees
- 8
- Beta
- 1.61
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.99) − 1 = — (DCF, example).